EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation

Yifei Guo, Jiajia Han, Yongmei Zhang, Chengmeng Jin, Yao Zhang, Jingjing He, Shiqi Chen, Yue Guo, Yanxue Lin, Fahong Li, Feifei Yang, Zhongliang Shen und 3 weitere

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1120300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Yifei Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious …. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Hepatitis B, Chronic. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described.

Methods

A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation.

Results

HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log 10 IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003).

Conclusions

EOT HBeAg negativity and anti-HBs ≥1.3 log 10 IU/L identify the low risk of HRV after PEG-IFN discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensHepatitis B, ChronicHumansHepatitis B e AntigensInterferon-alphaAntiviral AgentsCross-Sectional StudiesTreatment OutcomePolyethylene GlycolsHepatitis B AntibodiesDNA, ViralRecombinant ProteinsHepatitis B virus

Stichwörter der Autor:innen

HBeAgHBsAg reversionPEG-IFNanti-HBschronic hepatitis Bfunctional cure

Substanzen

Hepatitis B Surface AntigensHepatitis B e AntigensInterferon-alphaAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodiesDNA, ViralRecombinant Proteins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Institute of Infectious Diseases and Biosecurity, National Medical Center for Infectious Disea…
  • Department of Medical Microbiology and Parasitology, School of Medical Sciences, Fudan University, Shanghai, China.
  • Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Sh…
  • Department of Infectious Diseases, Jing'An Branch of Huashan Hospital, Fudan University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Y., Han, J., Zhang, Y., Jin, C., Zhang, Y., He, J., Chen, S., Guo, Y., Lin, Y., Li, F., Yang, F., Shen, Z., Mao, R., Zhu, H., & Zhang, J. (2023). End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1120300

Vancouver

Guo Y, Han J, Zhang Y, Jin C, Zhang Y, He J, et al. End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1120300

BibTeX
@article{Guo2023,
  author = {Guo, Yifei and Han, Jiajia and Zhang, Yongmei and Jin, Chengmeng and Zhang, Yao and He, Jingjing and Chen, Shiqi and Guo, Yue and Lin, Yanxue and Li, Fahong and Yang, Feifei and Shen, Zhongliang and Mao, Richeng and Zhu, Haoxiang and Zhang, Jiming},
  title = {End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1120300}
}
Kostenlos starten →